Drug Profile
TAS 121
Alternative Names: TAS-121Latest Information Update: 17 Aug 2018
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 17 Aug 2018 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Japan (PO) (Otsuka pipeline, August 2018)
- 14 Nov 2017 TAS 121 is still in phase I trials for Non-small-cell-lung-cancer (Late-stage disease, Second-line therapy or greater) in Japan
- 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in Japan (PO)